Advertisement

Topics

Cellerant Therapeutics, Inc. to Present Results of Phase 2 Clinical Trial of CLT-008 at American Society of Clinical Oncology (ASCO) 2018 Annual Meeting and European Hematology Association (EHA) 23rd Congress

09:00 EDT 17 May 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Cellerant Therapeutics, Inc., a clinical-stage company developing innovative immunotherapies for hematologic malignancies and other blood-related disorders, today announced that investigators from Cellerant’s recently complete...

Other Sources for this Article

Cellerant Therapeutics, Inc.
Rodney Young, 650-232-2122
Chief Financial Officer
info@cellerant.com

NEXT ARTICLE

More From BioPortfolio on "Cellerant Therapeutics, Inc. to Present Results of Phase 2 Clinical Trial of CLT-008 at American Society of Clinical Oncology (ASCO) 2018 Annual Meeting and European Hematology Association (EHA) 23rd Congress"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...